1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Hereditary Hemorrhagic Telangiectasia (HHT) Center" is currently closed and not accepting applications.
Hereditary Hemorrhagic Telangiectasia (HHT) Center is sponsored by HRSA. Supports centers dedicated to the diagnosis and treatment of HHT, aiming to improve health outcomes for affected individuals.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.
gov Maintenance Calendar View similar opportunities Hereditary Hemorrhagic Telangiectasia (HHT) Center Department of Health and Human Services Health Resources and Services Administration Document Type:Grants Notice Funding Opportunity Number:HRSA-26-092 Funding Opportunity Title:Hereditary Hemorrhagic Telangiectasia (HHT) Center Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Cooperative Agreement Category of Funding Activity:Health Expected Number of Awards:1 Assistance Listings:93.
110 -- Special Projects of Regional and National Significance Cost Sharing or Matching Requirement:No Last Updated Date:Jun 08, 2026 Original Closing Date for Applications:Jul 10, 2026 Electronically submitted applications must be submitted no later than 11:59 p. m. , ET, on the listed application due date.
Current Closing Date for Applications:Jul 10, 2026 Electronically submitted applications must be submitted no later than 11:59 p. m. , ET, on the listed application due date.
Archive Date:Aug 30, 2026 Estimated Total Program Funding:$ 2,900,000 Eligible Applicants:Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Additional Information on Eligibility:"Domestic" means the 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau.
## Additional Information Agency Name:Health Resources and Services Administration Description:The purpose of the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program is to reduce illness and death related to HHT by partnering with clinical center to expand access and coordination of care; creating innovative strategies that support clinicians with identifying and diagnosing HHT cases; and developing a de-identified, aggregate patient data registry to better understand this rare disease and its treatment outcomes.
Link to Additional Information:[](https://www. grants. gov/search-results-detail/361511) Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: ## Similar Opportunities (identified by AI) #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes.
To continue working, click on the "OK" button below. This is being done to protect your privacy. Unsaved changes will be lost.
According to the current listing, eligibility includes: Domestic public or private, non-profit or for-profit entities, including faith-based and community-based organizations. Confirm the full requirements in the official notice before applying.
The published deadline was July 10, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Hereditary Hemorrhagic Telangiectasia (HHT) Center is funded by HRSA. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
HRSA-27-006 and HRSA-27-007 post September 18, 2026 and both close October 19 — $711.4 million across 189 awards for service areas that already have a health center in them. The incumbent is defending. Everyone else is holding a free option.
Read articleHRSA-27-099 offers $125 million for 357 awards of $350,000 each to health centers with an active H80 award, closing September 9, 2026. An identical FY2026 round closed June 9 with the same money, the same award count, and a September 1 award date. Here is what back-to-back rounds mean for winners and losers of the first one, and why the 120-day implementation clause is the real commitment.
Read articleOn September 4, 2026, HRSA awarded $11.2 million through the Rural Residency Planning and Development program to build 15 new physician residencies across 14 states. Since 2019 the program has invested nearly $77 million, producing 66 accredited programs and 818 approved positions. Here is what the conversion rate reveals, why the specialty mix is narrowing, and how to build a competitive application for the next cycle.
Read article